- This topic is empty.
October 28, 2012 at 12:46 am #20718DeeeParticipant
I have been on this trial August 2012. There are not many people in Australia on this trial and I would like to reach out to anyone who is using the trial to discuss the side effects and usefulness of the medication so far.
There is little information from the hospital, since this is the first human trial.October 30, 2012 at 6:03 pm #57224
I hadn’t heard of this, here’s some info from NCI: trial listing: http://www.cancer.gov/clinicaltrials/search/view?cdrid=728588&version=HealthProfessional&protocolsearchid=10229932
Raf kinase inhibitor LGX818
An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)October 31, 2012 at 11:49 am #57225
Keith Flaherty at Mass General is running this trial and it is the Novartis version of the Braf/MEK dual therapy. It certainly is a viable option for those looking at interesting trials. It has a few internaitonal locations as well: http://www.cancer.gov/clinicaltrials/search/view?cdrid=728588&version=HealthProfessional&protocolsearchid=10229932November 8, 2012 at 3:24 pm #57226Catherine Poole wrote:
Keith Flaherty at Mass General is running this trial and it is the Novartis version of the Braf/MEK dual therapy. It certainly is a viable option for those looking at interesting trials. It has a few internaitonal locations as well:
I’ve been in that trial for 3 days now.
So far the side effects I’ve experienced are weird blurry vision that last for a few hours starting about an hour and a half after taking the LGX818 / MEK162, and the skin on my face is sensitive kind of like feeling wind burnt in the winter. In the 3 days I have already noticed a reduction in the size of my tumors.November 8, 2012 at 5:58 pm #57227
I’m sorry to hear about the side effects but very happy to hear about tumor reduction. How long have you been taking it? Where are you doing the trial?November 9, 2012 at 8:38 pm #57228 I’ve been on Novartis LGX818 and MEK162 since Monday. Keith Flaherty is my specialist and as such I’m doing the trial through MGH. The slot in the trial opened up last Tuesday and I spent the rest of last week doing the screening tests so I feel like I’ve been going non-stop for a while.November 9, 2012 at 10:26 pm #57229 Great! You are in good hands with Dr. Flaherty. He has provided MIF with a lot of support over the years and is a brilliant doctor.November 28, 2012 at 8:45 pm #57230patiParticipant Catherine, could you do an update on international locations for the Novartis RAF + MEK combination and also whether it is open to heavily pre-treated patients like yours truly? I contacted Dummer in Zurich but he said he does not have the combo only the LGX mono, I will contact my person in Novartis but I am not sure she would know,
PatiDecember 5, 2012 at 4:07 am #57231
I was told that LGX818 is the “top of the food chain” for BRAF drugs…December 5, 2012 at 1:03 pm #57232 I have reached out to Novartis to learn more. I will let you know what I find out. All of these therapies are early in trial so it is hard to make definitive judgement, but we are hopeful.
- The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.